Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study. Issue 4 (October 2022)

• Record Type: Journal Article
• Authors: Wray, Sibyl; Jacques, Francois; Miller, Tamara A; Nicholas, Jacqueline A; Arroyo, Rafael; Travis, Lori; Khatri, Bhupendra; Chirieac, Magdalena; Gandhi, Roopali; Roesch, Nora; Rodrigues, Amelie; Melas-Melt, Lydie; Rawlings, Andreea M; Hunter, Samuel F
• Is Part Of: Multiple sclerosis journal, experimental, translational and clinical. Volume 8:Issue 4(2022)
• Publication Date: 2022-10
• Subjects: Alemtuzumab -- disease-modifying therapies -- multiple sclerosis -- quality of life; Multiple sclerosis -- Periodicals; 616.834
• DOI: 10.1177/20552173221135888
• Languages: English
• ISSNs: 2055-2173

Abstract

Background: Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological function, and quality of life. Objective: To present results from the real-world PRO-ACT study in patients with multiple sclerosis who switched to alemtuzumab from another disease-modifying therapy. Methods: This 24-month, prospective, multicenter, observational study had a primary endpoint of change in overall satisfaction, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Secondary endpoints included the Multiple Sclerosis Impact Scale-29 (MSIS-29), Modified Fatigue Impact Scale-5 (MFIS-5), and the Patient-Determined Disease Steps (PDDS). Safety was monitored with adverse events (AEs). Results: Of 199 enrolled patients, improvements were observed in mean TSQM scores for overall satisfaction (baseline, 50.3; year 2, + 13.2; p < 0.0001), effectiveness (49.3 and + 12.2; p < 0.0001), and side effects (77.6 and + 4.5; p = 0.04). Improvements were also observed in MSIS-29 physical (52.4 and −6.0; p < 0.0001), MSIS-29 psychological (53.4 and −7.0; p = 0.0003), and MFIS-5 (12.8 and −1.7; p < 0.0001). Most (95.0%) patients experienced ≥ 1 AE (88.4% mild, 67.8% moderate). Conclusions: The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies.